<?xml version="1.0" encoding="UTF-8"?>
<p>The diagnosis of infectious diseases usually requires professional knowledge, sophisticated equipment and sufficient power sources; however, these are difficult to achieve in areas with poor economic foundations (
 <xref rid="b92-etm-0-0-09142" ref-type="bibr">92</xref>,
 <xref rid="b93-etm-0-0-09142" ref-type="bibr">93</xref>). The new generation of CRISPR-based molecular diagnostic technology [such as Specific High-sensitivity Enzymatic Reporter (SHERLOCK)] (
 <xref rid="b94-etm-0-0-09142" ref-type="bibr">94</xref>,
 <xref rid="b95-etm-0-0-09142" ref-type="bibr">95</xref>) do not rely on electricity as much as PCR, has lower cost, faster times and simple operation (
 <xref rid="b94-etm-0-0-09142" ref-type="bibr">94</xref>,
 <xref rid="b95-etm-0-0-09142" ref-type="bibr">95</xref>). The advantages of matching the efficiency and accuracy of qPCR technology have made significant contributions to the fight against Ebola outbreaks in Nigeria, where power is often lost (
 <xref rid="b92-etm-0-0-09142" ref-type="bibr">92</xref>,
 <xref rid="b93-etm-0-0-09142" ref-type="bibr">93</xref>).
</p>
